Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Haemonetics (HAE) Shares Outstanding (Weighted Average) (2016 - 2025)

Haemonetics has reported Shares Outstanding (Weighted Average) over the past 17 years, most recently at $46.8 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $46.8 million for Q4 2025, down 7.72% from a year ago — trailing twelve months through Dec 2025 was $46.8 million (down 7.72% YoY), and the annual figure for FY2025 was $50.3 million, down 0.74%.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $46.8 million at Haemonetics, down from $47.6 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for HAE hit a ceiling of $51.2 million in Q3 2022 and a floor of $46.8 million in Q4 2025.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $50.7 million (2023), compared with a mean of $50.3 million.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): grew 1.03% in 2021 and later fell 7.72% in 2025.
  • Haemonetics' Shares Outstanding (Weighted Average) stood at $51.0 million in 2021, then dropped by 0.94% to $50.5 million in 2022, then grew by 0.51% to $50.8 million in 2023, then dropped by 0.12% to $50.7 million in 2024, then decreased by 7.72% to $46.8 million in 2025.
  • The last three reported values for Shares Outstanding (Weighted Average) were $46.8 million (Q4 2025), $47.6 million (Q3 2025), and $48.1 million (Q2 2025) per Business Quant data.